EGFR and breast carcinoma: SCR potentially inhibits breast cancer by modulating core targets such as platelet-derived growth factor receptor, beta polypeptide, protein tyrosine kinase 2, and threonine kinase 1, which in turn affect pathways including the PI3K/AKT pathway, epidermal growth factor receptor pathway, and tumor necrosis factor pathway.